BR112017001116A2 - Composição compreendendo um éster de alfa- tocoferol para prevenção e tratamento da rinite alérgica - Google Patents

Composição compreendendo um éster de alfa- tocoferol para prevenção e tratamento da rinite alérgica

Info

Publication number
BR112017001116A2
BR112017001116A2 BR112017001116-6A BR112017001116A BR112017001116A2 BR 112017001116 A2 BR112017001116 A2 BR 112017001116A2 BR 112017001116 A BR112017001116 A BR 112017001116A BR 112017001116 A2 BR112017001116 A2 BR 112017001116A2
Authority
BR
Brazil
Prior art keywords
hydrogenated
oil
alpha
prevention
treatment
Prior art date
Application number
BR112017001116-6A
Other languages
English (en)
Other versions
BR112017001116A8 (pt
Inventor
Panin Giorgio
Lamprecht Jürgen
Original Assignee
Bio.Lo.Ga. S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51589387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017001116(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio.Lo.Ga. S.R.L. filed Critical Bio.Lo.Ga. S.R.L.
Publication of BR112017001116A2 publication Critical patent/BR112017001116A2/pt
Publication of BR112017001116A8 publication Critical patent/BR112017001116A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a uma composição para aplicação tópica, para uso na prevenção e no tratamento da rinite alérgica, consistindo em um éster de alfa-tocoferol selecionado do grupo consistindo em acetato, n-propionato e linoleato de tocoferila e um veículo oleoso selecionado do grupo consistindo em poli-isobuteno hidrogenado, polideceno hidrogenado e misturas de poli-isobuteno hidrogenado e/ou polideceno hidrogenado com poliolefinas hidrogenadas, em particular as poliolefinas hidrogenadas c6-c14, triglicerídeo caprílico/cáprico, olus oil, óleo de adansonia digitata, óleo de semente de adansonia digitata, cococaprilato/caprato, esqualano de oliva, esqualeno de oliva, óleo de semente de girassol (heliantus annus), cococaprilato, isononanoato de isononila, ciclopentassiloxano e misturas dos mesmos.
BR112017001116A 2014-07-22 2015-04-17 Composição compreendendo um éster de alfa-tocoferol para prevenção e tratamento da rinite alérgica BR112017001116A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2014A001332 2014-07-22
ITMI20141332 2014-07-22
PCT/EP2015/058368 WO2016012110A1 (en) 2014-07-22 2015-04-17 Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis

Publications (2)

Publication Number Publication Date
BR112017001116A2 true BR112017001116A2 (pt) 2018-01-23
BR112017001116A8 BR112017001116A8 (pt) 2022-07-05

Family

ID=51589387

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017001116A BR112017001116A8 (pt) 2014-07-22 2015-04-17 Composição compreendendo um éster de alfa-tocoferol para prevenção e tratamento da rinite alérgica

Country Status (24)

Country Link
US (1) US20170165226A1 (pt)
EP (1) EP3171873B1 (pt)
CN (1) CN106659709A (pt)
AR (1) AR101274A1 (pt)
AU (1) AU2015294663B2 (pt)
BR (1) BR112017001116A8 (pt)
CA (1) CA2955664C (pt)
CL (1) CL2017000058A1 (pt)
CO (1) CO2017000550A2 (pt)
CY (1) CY1122823T1 (pt)
DE (1) DE202014106007U1 (pt)
DK (1) DK3171873T3 (pt)
EA (1) EA201692486A1 (pt)
ES (1) ES2779525T3 (pt)
HR (1) HRP20200380T1 (pt)
HU (1) HUE049588T2 (pt)
LT (1) LT3171873T (pt)
MX (1) MX369991B (pt)
PE (1) PE20170437A1 (pt)
PL (1) PL3171873T3 (pt)
PT (1) PT3171873T (pt)
RS (1) RS60103B1 (pt)
SI (1) SI3171873T1 (pt)
WO (1) WO2016012110A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269835A (en) 1979-12-13 1981-05-26 Whittle Barry J Nasal composition for relieving nasal distress
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
DE4327089A1 (de) 1993-08-12 1995-02-16 Roshdy Ismail Mittel zur Behandlung von allergischen Erkrankungen der Atemwege
IT1282778B1 (it) * 1996-05-31 1998-03-31 Giorgio Panin Vitamina "e" acetato quale prodotto per applicazione topica
ITMI981586A1 (it) * 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
JP2003128552A (ja) 2001-08-16 2003-05-08 Rohto Pharmaceut Co Ltd 粘膜適用組成物
AU2003297294A1 (en) 2002-11-20 2004-06-15 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
JP2008266255A (ja) * 2007-04-24 2008-11-06 Project M:Kk アレルギー性疾患を予防および／または治療するための組成物
US20100076072A1 (en) 2008-07-25 2010-03-25 Northwestern University Compositions and methods of vitamin e administration
IT1393056B1 (it) * 2008-09-22 2012-04-11 Bio Lo Ga Srl Uso di vitamina e o suoi derivati per il controllo di artropodi
ITMI20090480A1 (it) * 2009-03-27 2010-09-28 Bio Lo Ga Srl Supporto tessile imbevuto di una composizione detergente/idratante
AU2012272652B2 (en) * 2011-06-24 2017-06-01 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators

Also Published As

Publication number Publication date
CN106659709A (zh) 2017-05-10
HRP20200380T1 (hr) 2020-08-07
PT3171873T (pt) 2020-02-25
CA2955664A1 (en) 2016-01-28
MX369991B (es) 2019-11-27
AR101274A1 (es) 2016-12-07
RS60103B1 (sr) 2020-05-29
LT3171873T (lt) 2020-04-10
EP3171873A1 (en) 2017-05-31
CA2955664C (en) 2022-09-06
MX2017000906A (es) 2017-05-12
EA201692486A1 (ru) 2017-07-31
AU2015294663B2 (en) 2019-11-21
US20170165226A1 (en) 2017-06-15
CL2017000058A1 (es) 2017-08-11
CY1122823T1 (el) 2021-05-05
SI3171873T1 (sl) 2020-07-31
DE202014106007U1 (de) 2015-07-23
AU2015294663A1 (en) 2017-01-19
EP3171873B1 (en) 2019-12-25
BR112017001116A8 (pt) 2022-07-05
ES2779525T3 (es) 2020-08-18
DK3171873T3 (da) 2020-03-16
CO2017000550A2 (es) 2017-03-31
PL3171873T3 (pl) 2020-07-13
WO2016012110A1 (en) 2016-01-28
PE20170437A1 (es) 2017-04-22
HUE049588T2 (hu) 2020-10-28

Similar Documents

Publication Publication Date Title
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
BR112015005743A2 (pt) derivados tricíclicos de quinoxalina e quinolina
BR112016027588B8 (pt) Sistema de aplicação em camadas para uma composição para tratamento de pele e método para aplicação de múltiplas doses de uma ou mais composições em uma área de tratamento de pele
MY165124A (en) Semifluorinated alkane compositions
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
BR112014017716A8 (pt) composições de ésteres de forbol, métodos para prevenir ou tratar acidente vascular cerebral e uso de ésteres de forbol
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY34899A (es) Derivados de estra-1,3,5(10), 16-tetraeno 3-sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, asi como su uso para la preparación de medicamentos
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
EA201990337A1 (ru) Композиция для местного применения с противогрибковой активностью
CL2020000918A1 (es) Composición sólida.
BR112016010072A8 (pt) conjugado, composição farmacêutica, usos do conjugado ou da composição farmacêutica, e de polissacarídeo de vi fragmentado, e, método para a fabricação de um conjugado
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
BR112019003594A2 (pt) sistemas depot que compreendem acetato de glatirâmero
HRP20191989T1 (hr) Farmaceutski pripravak za uporabu u povećanju trofizma sluznice nosa
CL2016001104A1 (es) Preparación farmacéutica y método de su producción y uso.
BR112015014262A2 (pt) formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, método de tratamento de rinite alérgica, uso de uma formulação farmacêutica, e, método para o tratamento de condição inflamatória e/ou alérgica
BR112017001116A2 (pt) Composição compreendendo um éster de alfa- tocoferol para prevenção e tratamento da rinite alérgica
GT201400146A (es) Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides
BR112016014182A2 (pt) Composições de ácidos graxos ômega 3 para tratar doenças que envolvem danos ao sistema nervoso
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
BR112014017048A8 (pt) emulsão orgânica compreendendo dha e epa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: HULKA S.R.L. (IT)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]